PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pyxis Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.76+0.08 (+4.76%)
Close on Oct 19, 2026
- Market cap
- $112.63M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
40.9%
34M of 83M shares
Institutional holders
76
9 new, 10 sold out
Net institutional buying
7M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $107.10K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bvf Inc/Il | 8,336,902 | 9.99% | 13G (passive) | Jul 2, 2026 |
| Lara Sullivan, M.D. | 7,543,007 | 11.21% | 13D (active) amendment | Mar 31, 2025 |
| Lara Sullivan | 6,624,699 | 10.30% | 13D (active) amendment | Dec 23, 2024 |
| Coastlands Capital LLC | 6,448,907 | 5.42% | 13G (passive) | Oct 1, 2026 |
| Laurion Capital Management LP | 4,796,479 | 7.72% | 13G (passive) amendment | Dec 31, 2025 |
| GordonMD Long Biased Master Fund LP | 3,834,740 | 6.20% | 13G (passive) | Jul 14, 2025 |
| Israel A. Englander | 3,542,663 | 5.70% | 13G (passive) | Jun 27, 2025 |
| Craig D. Gordon | 27,988,714 | 17.50% | 13G (passive) amendment | Oct 1, 2026 |
| GordonMD Long Biased GP LLC | 20,441,948 | 16.40% | 13G (passive) amendment | Oct 1, 2026 |
| GordonMD Global Investments LP | 10,024,909 | 12.10% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PYXS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| GordonMD Global Investments LP | 10,024,909 | 12.02% | $30.17M | +5,903,039 | 14.60% |
| Pfizer Inc | 7,032,770 | 8.43% | $19.48M | – | 11.43% |
| Laurion Capital Management LP | 4,900,888 | 5.88% | $14.75M | −96,445 | 0.38% |
| Vanguard Capital Management LLC | 2,075,997 | 2.49% | $6.25M | +42,487 | 0.00% |
| HealthInvest Partners AB | 966,459 | 1.16% | $2.91M | +769,423 | 0.78% |
| BlackRock, Inc. | 867,934 | 1.04% | $2.61M | +79,095 | 0.00% |
| Palo Alto Investors LP | 864,277 | 1.04% | $2.60M | −146,233 | 0.36% |
| Marshall Wace, Llp | 830,544 | 1.00% | $2.50M | +476,127 | 0.00% |
| Renaissance Technologies LLC | 772,232 | 0.93% | $2.32M | −116,448 | 0.00% |
| Geode Capital Management, LLC | 591,849 | 0.71% | $1.78M | −6,272 | 0.00% |
| Woodline Partners LP | 523,999 | 0.63% | $1.58M | New | 0.00% |
| 683 Capital Management, LLC | 459,367 | 0.55% | $1.38M | −436,896 | 0.07% |
| Jacobs Levy Equity Management, Inc | 428,606 | 0.51% | $1.29M | −32,391 | 0.00% |
| Longaeva Partners L.P. | 353,582 | 0.42% | $1.06M | −149,632 | 0.02% |
| Decheng Capital LLC | 326,810 | 0.39% | $983.70K | – | 0.13% |
| Vanguard Fiduciary Trust Co | 302,986 | 0.36% | $911.99K | +2,089 | 0.00% |
| Jane Street Group, LLC | 290,090 | 0.35% | $873.17K | −14,369 | 0.00% |
| State Street Corp | 248,837 | 0.30% | $749.00K | – | 0.00% |
| Millennium Management LLC | 233,004 | 0.28% | $701.34K | −164,621 | 0.00% |
| UBS Group AG | 155,217 | 0.19% | $467.20K | −98,907 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 76 | 34M | 40.9% | 9 / 24 | 24 / 10 | 8M | 2M |
| Q1 2026 | 78 | 28M | 33.1% | 14 / 11 | 36 / 14 | 4M | 4M |
| Q4 2025 | 79 | 30M | 36.2% | 22 / 24 | 19 / 14 | 9M | 6M |
| Q3 2025 | 73 | 27M | 32.2% | 14 / 11 | 31 / 15 | 5M | 5M |
| Q2 2025 | 74 | 28M | 33.0% | 15 / 21 | 23 / 30 | 4M | 7M |
| Q1 2025 | 89 | 30M | 36.3% | 13 / 22 | 26 / 22 | 2M | 4M |
| Q4 2024 | 99 | 32M | 37.8% | 25 / 32 | 20 / 18 | 12M | 8M |
| Q3 2024 | 92 | 28M | 33.5% | 23 / 29 | 17 / 9 | 7M | 5M |
| Q2 2024 | 80 | 28M | 33.8% | 25 / 20 | 21 / 16 | 8M | 2M |
| Q1 2024 | 71 | 23M | 27.6% | 30 / 22 | 5 / 9 | 15M | 1M |
| Q4 2023 | 51 | 9M | 10.6% | 9 / 11 | 12 / 11 | 2M | 1M |
| Q3 2023 | 54 | 8M | 9.4% | 14 / 15 | 13 / 7 | 1M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of PYXS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,422,296 | 1.71% | $4.28M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 558,775 | 0.67% | $1.68M | 0.00% | Jun 30, 2026 |
| iShares Biotechnology ETF | 374,680 | 0.45% | $1.13M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 271,545 | 0.33% | $488.78K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 166,564 | 0.20% | $501.36K | 0.03% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 90,276 | 0.11% | $162.50K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 78,709 | 0.09% | $141.68K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 70,060 | 0.08% | $210.88K | 0.14% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 38,072 | 0.05% | $68.53K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 26,866 | 0.03% | $80.87K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 26,650 | 0.03% | $80.22K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 11,188 | 0.01% | $33.68K | 0.02% | Jun 30, 2026 |
| U.S. Micro Cap Portfolio | 10,263 | 0.01% | $27.20K | 0.00% | Jul 31, 2026 |
| Victory Extended Market Index Fund | 5,968 | 0.01% | $15.82K | 0.00% | Jul 31, 2026 |
| JNL/DFA U.S. Small Cap Fund | 3,922 | 0.00% | $11.81K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Thomas Civik | CEO & Chairman of the Board, Director | 221,886 | 0.27% | Sep 8, 2026 |
| Lara Sullivan | President ,CEO & CMO, Director | 2,403,882 | 2.88% | Apr 2, 2025 |
| Jitendra Wadhane | Prin Fin & Acct Officer | 512,882 | 0.61% | Mar 25, 2026 |
| Pamela Ann Connealy | CFO & COO | 3,425,179 | 4.11% | Apr 2, 2025 |
| Jakob Dupont | Director | 73,741 | 0.09% | Aug 20, 2026 |
| Santhosh Palani | Director | 6,000 | 0.01% | Mar 25, 2026 |
| Michael A. Metzger | Director | – | – | Mar 25, 2026 |
| Freda C. Lewis-Hall | Director | 241,405 | 0.29% | Mar 25, 2026 |
| Rachel Humphrey | Director | 81,309 | 0.10% | Mar 25, 2026 |
| John L. Flavin | Director | 413,015 | 0.50% | Mar 25, 2026 |
| Darren S. Cline | Director | 251,405 | 0.30% | Mar 25, 2026 |
| Long Biased Master Fund LP GordonMD | 10% owner | – | – | Jul 10, 2026 |
| Long Biased GP LLC GordonMD | 10% owner | 10,024,909 | 12.02% | Jul 10, 2026 |
| Craig D. Gordon | 10% owner | – | – | Jul 10, 2026 |
| Global Investments LP GordonMD | 10% owner | – | – | Jul 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jakob Dupont Director | Jun 30, 2026 | Option exercise | +35,000 | $1.60 | $56.00K | 73,741 |
| Jakob Dupont Director | Jun 30, 2026 | Sale(10b5-1 plan) | −35,000 | $3.06 | $107.10K | 38,741 |
| Jitendra Wadhane Prin Fin & Acct Officer | Mar 24, 2026 | Award | +109,461 | – | – | 512,882 |
| Rachel Humphrey Director | Apr 21, 2025 | Sale(10b5-1 plan) | −13,896 | $1.03 | $14.31K | 81,309 |
| Rachel Humphrey Director | Apr 17, 2025 | Sale(10b5-1 plan) | −200 | $0.97 | $194 | 95,205 |
| Rachel Humphrey Director | Apr 14, 2025 | Sale(10b5-1 plan) | −1,400 | $0.97 | $1.36K | 95,405 |
| Pamela Ann Connealy CFO & COO | Nov 26, 2024 | Buy | +83,400 | $1.96 | $163.46K | 1,199,143 |
| Pamela Ann Connealy CFO & COO | Nov 26, 2024 | Buy | +5,450 | $2.00 | $10.90K | 1,115,743 |
| Santhosh Palani Director | Jun 7, 2024 | Award | +6,000 | – | – | 6,000 |
| Freda C. Lewis-Hall Director | Mar 26, 2024 | Award | +35,219 | – | – | 241,405 |
| Jitendra Wadhane SVP, Chief Accounting Officer | Mar 26, 2024 | Award | +131,484 | – | – | 398,421 |
| Rachel Humphrey Director | Mar 26, 2024 | Award | +38,741 | – | – | 96,805 |
| John L. Flavin Director | Mar 26, 2024 | Award | +35,219 | – | – | 413,015 |
| Jakob Dupont Director | Mar 26, 2024 | Award | +38,741 | – | – | 38,741 |
| Pamela Ann Connealy CFO & COO | Mar 26, 2024 | Award | +328,710 | – | – | 1,110,293 |
| Darren S. Cline Director | Mar 26, 2024 | Award | +35,219 | – | – | 251,405 |
| Pamela Ann Connealy CFO and COO | Nov 29, 2023 | Tax withholding | −36,949 | $1.40 | $51.73K | 781,583 |
| Jitendra Wadhane Chief Accounting Officer | Nov 15, 2023 | Award | +40,000 | – | – | 266,937 |
| Pamela Ann Connealy CFO and COO | Sep 28, 2023 | Buy | +8,000 | $1.87 | $14.96K | 818,532 |
| Pamela Ann Connealy CFO and COO | Sep 27, 2023 | Buy | +6,426 | $1.85 | $11.89K | 810,532 |
| Jitendra Wadhane Chief Accounting Officer | Sep 27, 2023 | Buy | +2,500 | $1.87 | $4.68K | 226,937 |
| Pamela Ann Connealy CFO and COO | Sep 25, 2023 | Buy | +12,000 | $1.67 | $20.04K | 804,106 |
| Jitendra Wadhane Chief Accounting Officer | Sep 25, 2023 | Buy | +5,000 | $1.77 | $8.85K | 224,437 |
| Jitendra Wadhane Chief Accounting Officer | Sep 22, 2023 | Buy | +2,500 | $1.74 | $4.35K | 219,437 |
| Pamela Ann Connealy CFO and COO | Sep 22, 2023 | Buy | +5,000 | $1.74 | $8.70K | 792,106 |
| Lara Sullivan President and CEO, Director | Sep 18, 2023 | Sale | −8,541 | $2.10 | $17.94K | 2,403,882 |
| Lara Sullivan President and CEO, Director | Sep 14, 2023 | Sale | −100 | $2.25 | $225 | 2,412,423 |
| Lara Sullivan President and CEO, Director | Sep 13, 2023 | Tax withholding | −184,742 | $2.13 | $393.50K | 2,412,523 |
| Lara Sullivan President and CEO, Director | Sep 13, 2023 | Sale | −3,000 | $2.27 | $6.81K | 2,597,265 |
| Lara Sullivan President and CEO, Director | Sep 12, 2023 | Sale | −4,917 | $2.25 | $11.06K | 2,600,265 |
| Lara Sullivan President and CEO, Director | Sep 11, 2023 | Sale | −20,000 | $2.27 | $45.40K | 2,605,182 |
| Pamela Ann Connealy CFO and COO | Sep 7, 2023 | Award | +187,793 | – | – | 782,106 |
| Jitendra Wadhane Chief Accounting Officer | Sep 7, 2023 | Award | +93,896 | – | – | 211,937 |
| Lara Sullivan President and CEO, Director | Sep 7, 2023 | Award | +469,483 | – | – | 2,625,182 |
| Jay Feingold Chief Medical Officer | Mar 24, 2023 | Award | +209,803 | – | – | 730,345 |
| Lara Sullivan President and CEO, Director | Mar 24, 2023 | Award | +703,379 | – | – | 2,155,699 |
| Pamela Ann Connealy CFO and COO | Mar 24, 2023 | Award | +209,803 | – | – | 594,313 |
| John L. Flavin Director | Mar 24, 2023 | Award | +139,355 | – | – | 377,796 |
| Freda C. Lewis-Hall Director | Mar 24, 2023 | Award | +139,355 | – | – | 206,186 |
| Rachel Humphrey Director | Mar 24, 2023 | Award | +58,064 | – | – | 58,064 |
| Darren S. Cline Director | Mar 24, 2023 | Award | +139,355 | – | – | 216,186 |
| Jitendra Wadhane Chief Accounting Officer | Mar 24, 2023 | Award | +45,000 | – | – | 88,648 |
| Jitendra Wadhane Chief Accounting Officer | Mar 24, 2023 | Award | +29,393 | – | – | 118,041 |
| Thomas Civik Director | Mar 24, 2023 | Award | +139,355 | – | – | 206,186 |
| Inc Pfizer 10% owner | Mar 17, 2023 | Buy | +1,811,594 | $2.76 | $5.00M | 5,952,263 |
| Inc Pfizer 10% owner | Mar 17, 2023 | Buy | +1,811,594 | $2.76 | $5.00M | 5,952,263 |
| Jay Feingold Chief Medical Officer | Jan 3, 2023 | Award | +53,931 | – | – | 520,542 |
| Pamela Ann Connealy Chief Financial Officer | Jan 3, 2023 | Award | +43,493 | – | – | 384,510 |
| Lara Sullivan Chief Executive Officer, Director | Jan 3, 2023 | Award | +95,684 | – | – | 1,452,320 |
| Mark Chin – | Apr 21, 2022 | Sale | −1,745,761 | $3.05 | $5.32M | 0 |
| Jay Feingold Chief Medical Officer | Apr 14, 2022 | Award | +115,931 | – | – | 466,611 |
| Lara Sullivan Chief Executive Officer, Director | Apr 14, 2022 | Award | +315,273 | – | – | 1,356,636 |
| Pamela Ann Connealy Chief Financial Officer | Apr 14, 2022 | Award | +93,493 | – | – | 341,017 |
| Darren S. Cline Director | Mar 31, 2022 | Award | +66,831 | – | – | 76,831 |
| Jay Feingold Chief Medical Officer | Mar 31, 2022 | Award | +306,930 | – | – | 350,680 |
| Thomas Civik Director | Mar 31, 2022 | Award | +66,831 | – | – | 66,831 |
| Pamela Ann Connealy Chief Financial Officer | Mar 31, 2022 | Award | +247,524 | – | – | 247,524 |
| John L. Flavin Director | Mar 31, 2022 | Award | +66,831 | – | – | 238,441 |
| Freda C. Lewis-Hall Director | Mar 31, 2022 | Award | +66,831 | – | – | 66,831 |
| Lara Sullivan Chief Executive Officer, Director | Mar 31, 2022 | Award | +742,574 | – | – | 1,041,363 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jakob Dupont Director | Jun 30, 2026 | 35,000 | $107.03K | Jun 30, 2026 | Stock Option Exercise |
| Rachel Humphrey Director | Apr 21, 2025 | 13,896 | $14.36K | Apr 21, 2025 | Restricted Stock Vesting |
| Rachel Humphrey Director | Apr 17, 2025 | 200 | $194 | Apr 17, 2025 | Restricted Stock Vesting |
| Rachel Humphrey Director | Apr 14, 2025 | 1,400 | $1.36K | Apr 14, 2025 | Restricted Stock Vesting |
| Lara Sullivan Officer, Director | Sep 18, 2023 | 8,541 | $17.94K | Sep 18, 2023 | Restricted Stock Vesting |
| Lara Sullivan Officer, Director | Sep 14, 2023 | 100 | $225 | Sep 14, 2023 | Restricted Stock Vesting |
| Lara Sullivan Officer, Director | Sep 13, 2023 | 3,000 | $6.82K | Sep 13, 2023 | Restricted Stock Vesting |
| Lara Sullivan Officer, Director | Sep 12, 2023 | 4,917 | $11.07K | Sep 12, 2023 | Restricted Stock Vesting |
| Lara Sullivan Officer, Director | Sep 11, 2023 | 20,000 | $45.41K | Sep 11, 2023 | Restricted Stock Vesting |
| Jay Feingold Former Chief Medical Officer | Sep 5, 2023 | 18,109 | $42.92K | Sep 5, 2023 | Option Granted - 08/16/2021 |
| Jay Feingold Former Chief Medical Officer | Aug 11, 2023 | 50,000 | $126.48K | Aug 11, 2023 | Restricted Stock Vesting |
| Jay Feingold Former Chief Medical Officer | Aug 1, 2023 | 25,000 | $63.07K | Aug 1, 2023 | Restricted Stock Vesting |
| Jay Feingold Former Chief Medical Officer | Jul 31, 2023 | 25,000 | $64.60K | Jul 31, 2023 | Restricted Stock Vesting |
| Jay Feingold Former Chief Medical Officer | Jul 28, 2023 | 23,021 | $56.01K | Jul 27, 2023 | Restricted Stock Vesting |
| Jay Feingold Former Chief Medical Officer | Jul 27, 2023 | 23,021 | $56.01K | Jul 27, 2023 | Restricted Stock Vesting |